Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
Abstract
Stage III NSCLC represents a heterogeneous disease for which optimal treatment continues to pose a clinical challenge. Recent changes in the American Joint Commission on Cancer staging to the eighth edition has led to a shift in TNM stage grouping and redefined the subcategories (IIIA–C) in stage III NSCLC for better prognostication. Although concurrent chemoradiotherapy has remained standard-of-care for stage III NSCLC for almost 2 decades,...
Paper Details
Title
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
Published Date
Mar 1, 2020
Journal
Volume
15
Issue
3
Pages
324 - 343
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History